Perjeta + Herceptin fails in JACOB trial to treat HER2-positive metastatic gastric or gastro-oesophageal junction cancer.Roche
In The Lancet Oncology, Josep Tabernero and colleagues report the final analysis of the JACOB trial, which tested the efficacy and safety of pertuzumab (a monoclonal antibody targeting HER2 receptors) combined with trastuzumab and chemotherapy from Roche, in previously untreated patients with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.
JACOB was the first trial to investigate a dual HER2 blockade in metastatic gastric cancer; unfortunately, no significant improvement in overall survival was observed in the group treated with the dual-HER2 targeted combination.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.